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Abstract 
Objective  
Positive mood on the day of vaccination has been associated with subsequent 
antibody responses to the influenza vaccine in older adults. The primary aim of this trial was 
to examine whether a brief intervention was able to enhance positive mood at the time of 
vaccination in a clinical context. Secondary aims included exploratory analyses of the effects 
of the intervention on non-specific and influenza-specific immunity.  
Methods  
One hundred and three older adults (65-85 years) participated in a two-arm, parallel, 
single-blind, randomised controlled trial. Participants viewed either a 15-minute video 
package designed to induce positive mood or a matched neutral control video, immediately 
prior to receiving a standard dose quadrivalent influenza vaccination. State affect and 
secretory IgA levels were assessed immediately prior to, and following, the interventions. 
Antigen-specific IgG responses to the vaccination were assessed at 4 and 16-weeks post-
vaccination. 
Results 
The positive mood intervention resulted in significant improvements in state positive 
affect, compared with the neutral control. Secretory IgA levels significantly increased across 
both groups. Antigen-specific IgG responses to influenza vaccination were not statistically 
significantly different between groups, although point-estimates of effect size favoured 
participants who viewed the positive mood intervention for most strains at both 4 and 16-
weeks post-vaccination. 
Conclusions  
A 15-minute intervention can improve positive mood in older adults prior to 
vaccination. Future trials should examine whether enhancing mood at the time of vaccination 
could enhance the effectiveness of influenza vaccination on patients and benefit health 
services. 
Keywords: Positive affect, intervention, positive mood, vaccination, immunity, 
psychoneuroimmunology 
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03144518  
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 The protection afforded by the annual seasonal influenza vaccination is considerably 
lower in older adults compared to younger adults (Goodwin, Viboud, & Simonsen, 2006), in 
part due to age-related declines in immunological competence (Reber et al., 2012). This 
leaves older adults at an increased risk of the most serious complications associated with 
influenza infection, with 90% of influenza-related deaths in industrialised countries occurring 
in those aged over 65 years (Thompson, Shay, & Weintraub, 2003). To date, advances to 
improve influenza vaccine responses in older adults have primarily focused on 
pharmacological solutions. These have met with some success with adjuvanted influenza 
vaccines, that contain an additional component that stimulates a heightened immune 
response, and high-dose vaccines, that include a four times greater amount of each influenza 
antigen, showing improved protection in older adults in recent years (DiazGranados et al., 
2014; Domnich et al., 2017). However, even with the increasing adoption of these enhanced 
vaccine formulations, reduced vaccine efficacy in older adults remains problematic. For 
example, the adjuvanted trivalent (i.e., containing three strains) influenza vaccine adopted by 
many countries for the most recent influenza season (2018/19), was reported to have an 
estimated effectiveness of around 51% against hospitalisations for influenza/pneumonia in 
community dwelling older adults (Domnich et al., 2017). This indicates calls to research and 
develop novel approaches to improve vaccine responses in this population  (e.g., Kelly & 
Valenciano, 2012; Lang, Govind, Mitchell, Siegrist, & Aspinall, 2011; Lang et al., 2012) 
remain highly relevant. 
One alternative to enhancing vaccine responses in older adults are psychological and 
behavioural interventions. Psychological and behavioural factors have been shown to 
influence the dynamics of the immune system, in turn modifying responses to antigenic 
challenge (e.g., Calder, 2013; Pascoe, Fiatarone Singh, & Edwards, 2014; Pedersen, 
Zachariae, & Bovbjerg, 2009; Prather et al., 2012). To give some examples: chronically 
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stressed older adult spousal carers show blunted immune responses to influenza vaccination 
compared to age-matched non-carers (Kiecolt-Glaser, Glaser, Gravenstein, Malarkey, & 
Sheridan, 1996; Vedhara et al., 1999); a single night of sleep deprivation in young adults 
results in a nearly two-fold reduced antibody response to hepatitis A vaccination at 4 weeks 
post-vaccination compared to those who sleep normally (Lange, 2003); and salivary antibody 
secretions to an orally ingested antigen have been shown in longitudinal studies to be 
differentially influenced by both positive and negative life events (Stone, Cox, 
Valdimarsdottir, Jandorf, & Neale, 1987; Stone et al., 1994). More recently in a prospective 
cohort study examining the effects of multiple lifestyle factors and psychological well-being 
on the response to influenza vaccination in older adults (Ayling et al., 2018), we identified 
that positive affect, in particular on the day of vaccination, was associated with enhanced 
short and long-term antibody responses to the weakest immunogenic strain of the influenza 
vaccination.  
The mechanisms by which positive affect influences immune function continue to be 
elucidated (for reviews of this topic see Dockray & Steptoe, 2010; Marsland, Pressman, & 
Cohen, 2007; Pressman, Jenkins, & Moskowitz, 2019). Indirect influences of positive affect 
via health behaviours have been shown to impact immune function (e.g., sleep, nutrition, 
physical activity). Similarly, direct effects have also been reported via the activation of 
neuroendocrine systems responsible for the release of hormones, such as cortisol and 
norepinephrine, which in turn interact with immune cells via receptors on their surface 
(Marques-Deak, Cizza, & Sternberg, 2005). Further, there are well established anatomical 
links between the central nervous and immune systems, including the direct innervation of 
lymphatic organs (Felten & Felten, 1991; Nance & Sanders, 2007) that can potentially be 
triggered by positive affect. As such there are multiple, biologically plausible mechanisms by 
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which a positive affect intervention could influence immunity, and in turn, antibody 
responses to vaccination. 
In view of previous observational evidence that positive mood on the day of 
vaccination is associated with enhanced antibody responses; and the presence of plausible 
biological pathways to explain this effect, we designed a study to explore whether we could 
enhance positive mood in older people immediately prior to vaccination. The study was a 
randomised controlled trial in which participants were randomised to view either a novel 
positive mood intervention on a digital platform (15 minutes long) or neutral control material 
also 15 minutes in duration and delivered on the same digital platform. Our primary aim was, 
therefore, to examine whether our positive mood intervention resulted in greater positive 
mood compared with the neutral control.  The secondary aims, were to: explore the effect on 
an immediate immune parameter (secretory IgA) previously shown to be sensitive to positive 
mood inductions (e.g., Pawlow & Jones, 2005; Yamamoto & Nagata, 2011) and vaccine-
specific IgG responses, as a surrogate of vaccine effectiveness. We also examined the 
moderating effects of perceived health status and psychological traits on mood and immune 
responses to the intervention; and the feasibility of a future definitive trial by examining 
participant recruitment levels, attrition, and numbers receiving the intervention as intended.  
Method 
Study Design  
The study was a two-arm, parallel, single-blind, randomised controlled trial conducted 
between August 2017 and May 2018. Research governance and ethical approval for this 
study was given by the Health Research Authority and East Midlands - Nottingham Research 
Ethics Committee 1 (17/EM/0198) prior to study commencement. The study was pre-
registered at clinicaltrials.gov (NCT03144518).  
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Participants 
One hundred and three older adults (65-85 years) eligible to receive the 2017-18 
influenza vaccination participated in the study. Participants were identified through two 
primary care practices in Nottingham, UK. Given the influence of prior vaccination history 
on subsequent immune responses to vaccination (Sasaki et al., 2008), recruitment was limited 
to those who had received the influenza vaccination the previous year (2016/17). The purpose 
of this was to minimise between-person differences in previous exposure to influenza and 
influenza vaccination and the concomitant effects on antibody levels prior to vaccination. 
Alternative approaches including statistically controlling for vaccine history or recruiting 
only participants who had not previously received an influenza vaccination were rejected due 
to concerns with poor record keeping and reduced generalisability respectively. Exclusion 
criteria were kept minimal to maximise generalisability. They included: deemed by health 
care provider to be too physically frail to participate; diagnosed with a cognitive condition 
(e.g., dementia) that would make participation difficult; to have insufficient command of the 
English language; being sufficiently impaired of hearing or vision that exposure to the 
intervention or neutral video content as intended would be compromised; or having a 
contraindication for influenza vaccination or venepuncture.  
Randomisation 
Randomisation to condition was done using a computer-generated block 
randomisation sequence (block size = 10) on a 1:1 allocation ratio, initiated by the lead author 
(KA). This randomly generated sequence was matched to participant ID numbers (assigned in 
order of response to invitation letter) in such a manner that touchscreen computer tablets were 
programmed to play either the positive mood or neutral control content, without the 
researchers being aware of participant assignment.  
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Procedure 
Eligible patients at each primary care practice were sent an invitation letter detailing 
the study and providing researcher contact details. Participants were informed the purpose of 
the study was to explore the effects of mood on influenza vaccination and that they would be 
asked to watch a short video. They were not told that there were positive mood and neutral 
control conditions. Interested individuals contacted the research team via email, telephone, or 
by returning a reply slip provided with a freepost envelope. After discussing the study with 
the researchers, those who agreed to participate were sent a detailed information sheet, 
consent form, and baseline questionnaire to complete and return via post. This questionnaire 
included sections on demographic information, perceived health status, and trait 
psychological characteristics related to affective experience.  
Participants then attended a session at their local primary care practice (maximum of 
six participants per session) where they had a pre-vaccination blood sample taken (8ml), 
height and weight measured, and provided a pre-intervention saliva sample for the 
measurement of secretory IgA. Participants were then given a demonstration of how to use a 
touchscreen computer tablet device (Model: ASUS-T101HA) to complete the state affect 
measures, with a small minority opting to complete measures using printed questionnaires 
(n=3, 2.9%). Participants then completed pre-intervention measures (approximately 5 
minutes) and viewed either the positive mood intervention video or neutral control video on 
an individual tablet device wearing over-ear headphones, followed by completion of the post-
intervention measures. For those completing measures on the tablet (presented using 
OpenSesame software: Mathot, Schreij, & Theeuwes, 2012) - the order of scale presentation 
(and any items within those scales) was randomised to minimise order effects. Participants 
then provided a further saliva sample and had a standard dose of the quadrivalent 2017/18 
seasonal influenza vaccine administered. The vaccine was administered by a practice nurse or 
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health care assistant within five minutes of completing the intervention.  Participants returned 
for follow-up blood samples at four and 16-weeks post-vaccination. Health-care utilization 
attributable to influenza-like symptoms was assessed by the lead author (KA) who consulted 
medical records at six months post-vaccination noting any consultations during the prior six 
months where influenza-like symptoms were assigned read-codes or noted in free-text entries 
(e.g., runny nose, sore throat, fever), antibiotic prescriptions not clearly attributable to another 
cause (e.g., urinary tract infection), and where additional investigations related to influenza-
like symptoms were ordered (e.g., chest X-ray). Participants received £20 inconvenience 
payments for taking part in the study. Materials and stimuli used in the study can be accessed 
at osf.io/u7h36.1 
Positive Mood Intervention Condition 
Participants in the positive mood condition viewed a video lasting 15 minutes and 30 
seconds specifically developed to increase state affect in older adults. Most previous brief 
positive affect interventions have been developed for use in young adults and without a 
clinical context in mind. The development of the intervention is the subject of a related 
manuscript (Ayling et al., in preparation). In brief, the intervention was iteratively developed 
following a systematic review of brief interventions that induced positive mood and measured 
immunity, qualitative focus groups and interviews with older adults and health care 
professionals, and co-development alongside patient and public involvement partners. These 
led to some key guiding principles that the intervention should be presented individually, 
made up of high arousal stimuli in multiple forms (e.g., uplifting music, images, ‘classic’ 
comedy) to appeal to different tastes, and be around 15 minutes in duration due to the 
constraints of a primary care clinical context. Thus, the resulting intervention was a 
                                                 
1 Please note that while UK copyright laws permitted the limited use of copyright protected works used in the interventions for non-commercial 
research purposes in the UK at the time this research was conducted (see https://www.gov.uk/guidance/exceptions-to-copyright), copyright 
restrictions may apply in other countries or as a result of subsequent legislation changes in the UK.  
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combination of these elements. A description of the specific intervention stimuli and the 
intervention itself can be viewed at osf.io/u7h36. Prior piloting of the intervention in older 
adults outside of a clinical context indicated that the intervention was successful in inducing 
significant positive affect increases assessed on a visual analogue scale of happiness (Kontou, 
Thomas, & Lincoln, 2012), and a pictorial scale of positive affect (see below), but not the 
positive and negative affect schedule (Watson, Clark, & Tellegen, 1988).  
Neutral Control Video 
Participants in the control condition viewed a video designed to match key features of 
the positive mood intervention video (e.g., length, format), but with neutral emotional 
content. For example, videos included documentary and lecture clips, music judged to be 
non-emotive, and images with neutral emotional valence from the Nencki Affective Picture 
System (Marchewka, Zurawski, Jednoróg, & Grabowska, 2014). 
Measures 
Baseline/trait measures. Perceived health status was measured using the 12 item 
Health Status Questionnaire 2.0 (Barry, Kaiser, & Atwood, 2007). Participants indicated the 
extent to which they experienced a variety of health-related difficulties (e.g., “How much 
bodily pain have you had during the past 4 weeks?”) on Likert-type scales. Items covered a 
broad range of health-relevant domains including physical functioning, social functioning, 
bodily pain, and mental health. Responses were weighted in accordance with published 
guidelines and summed to calculate a total perceived health status score ( = .91), with 
higher scores indicating greater perceived health.  
Trait positive and negative affect were measured using the Positive and Negative 
Affect Schedule (Watson et al., 1988). Participants were presented with 10 positive (e.g., 
excited) and 10 negative (e.g., ashamed) emotion adjectives, which they were asked to rate 
the extent to which they felt that way ‘‘in general” on a five-point scale (“very slightly or not 
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at all” – “extremely)”. Positive (α = .92) and negative affect subscales (α = .92) were created 
by summing the scores of positive and negative adjectives respectively, with higher scores 
indicating greater trait positive and negative affect respectively.  
Trait optimism was measured using the Revised Life Orientation Test (Scheier, 
Carver, & Bridges, 1994). Participants were asked to indicate the extent to which they agreed 
with 10 statements about themselves (e.g. “In uncertain times, I usually expect the best”) on a 
five-point scale ranging from “strongly disagree” to “strongly agree”. Four items were filler 
questions, with the remaining six used to compute a trait optimism score (α = .73) with higher 
scores indicating with greater optimism. 
Trait emotional reactivity was measured using the 21-item Emotional Reactivity Scale 
(Nock, Wedig, Holmberg, & Hooley, 2008). Participants were asked to indicate the extent to 
which they felt particular statements reflect themselves (e.g., “I experience emotions very 
strongly”) on a five-point scale ranging from “not at all like me” to “completely like me”. 
Items scores were then summed (α = .96), with greater scores indicating greater trait 
emotional reactivity. 
State affect measures. Prior to, and immediately following, viewing either the 
positive mood or neutral control video all participants completed the Affective Slider (Betella 
& Verschure, 2016), the state version of the Positive and Negative Affect Schedule (Watson 
et al., 1988), and an internally developed pictorial measure of positive affect tailored for older 
adults (described below). The primary outcome measure was the Affective Slider, as prior 
piloting of the intervention in community samples raised concerns regarding sensitivity of the 
Positive and Negative Affect Schedule to acute changes in mood, and the pictorial measure 
had not yet gone through robust reliability testing. 
Affective slider. Participants were asked to place a mark representing “how you feel 
right now, that is, at the present moment”, on two horizontal sliding visual analogue scales 
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representing emotional valence and arousal. Each scale was presented with corresponding 
cartoon faces depicting high and low levels of pleasure and arousal respectively. Scores range 
from 0 to 100 with higher scores indicating greater pleasure and arousal (hereafter referred to 
as slider-valence and slider-arousal scores). The Affective Slider has previously been shown 
to compare favourably against the Self-Assessment Manikin and be responsive to affective 
stimuli (Betella & Verschure, 2016). 
Positive and negative affect schedule (PANAS). The state version of this scale 
(Watson et al., 1988) consists of 20 emotion adjectives for which participants indicated the 
extent to which they felt that way “right now, that is, at the present moment” - on a five-point 
scale. Positive (mean α = .89) and negative affect subscales (mean α = .89) were created by 
summing the scores of positive and negative adjectives respectively. 
 Pictorial scale of positive affect. Participants completed a single-item photo-based 
measure of positive affect tailored for older adults, the development of which is the subject of 
a different manuscript (Ayling et al., in preparation). Participants were presented with six 
groups of images (including older adult faces) depicting varying degrees of positive affect, 
ranging from neutral to extremely happy. They were then asked to select the group of images 
which best reflected “how you feel right now, that is, at the present moment”. Piloting in 
community samples showed this scale was sensitive to mood induction, and significantly 
positively correlated with the neutral-happy dimension of the revised Visual Analogue Mood 
Scale (Kontou et al., 2012), and the state version of the PANAS positive affect scale.  
Immune Measures 
Antigen specific IgG. Venous blood samples (8 ml) were obtained for the 
measurement of IgG antibody levels at baseline, 4 weeks post-vaccination, and 16 weeks 
post-vaccination. The rationale for the timings of blood samples was that IgG antibody levels 
are at their peak approximately 4 weeks post-vaccination (Gross et al., 1996), whereas 16 
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weeks post-vaccination coincides with the anticipated peak of influenza incidence in the UK 
(i.e., January-March) at which point sustained high levels of antibody may be of particular 
clinical benefit. After clotting at room temperature, samples were centrifuged at 2000g for 10 
minutes after which sera were separated and stored at -20°C until analysis. Influenza IgG 
antibodies for each of the strains contained in the vaccine were measured via enzyme-linked 
immunoassay (ELISA). The following description outlines the protocol used, with aspiration 
and washes with three cycles of 80 l 0.05% Tween-20 solution in phosphate buffered saline 
(PBS) occurring between each step, with all incubations at room temperature unless 
otherwise stated. All samples were analysed in duplicate (samples mean intra-assay CV = 
3.97%) with dilutions and pipetting into plates were performed by using a computerised 
pipetting system (Precision XS, BioTek) for accuracy. 
 Antigens (A/Hong-Kong/4801/2014; A/Michigan/45/2015; B/Brisbane/60/2008; 
B/Phucket/3073/2013; National Institute of Biological Standards and Control) were diluted to 
0.5 gHA/ml, 1 gHA/ml, 0.25 gHA/ml, and 0.25 gHA/ml respectively in carbonate-
bicarbonate buffer with 20 l added to 384-well plates (NUNC MaxiSorp, Thermo Fisher 
Scientific). Alongside this, 15 two-fold serial human IgG dilutions (top dilution 2 g/ml; 
Merek) were added in duplicate (20 l) to each plate to form a calibration curve and left at 
4°C overnight. Wells were then blocked with 40 l of 3% bovine serum albumin in PBS for 1 
hour. Sera diluted at 1:4000 in PBS was added in duplicate (20 l) for each antigen for two 
hours. PBS was added to the calibration curve for the same period. Following this, 20 l of 
biotinylated anti-human IgG (vector labs) diluted to 1:320000 in PBS was added for a further 
2 hours. Streptavidin-HRP (R&D systems) diluted at 1:40 in PBS was then added to wells for 
15 minutes. Finally, 20 l of tetramethylbenzidine substrate solution (Sigma-Aldrich) was 
added to each well for 10 min, before the reaction was stopped with 20 l of 1N sulphuric 
acid. Plates were then scanned at 450 nm on a GloMax Explorer instrument (Promega). 
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Signals from samples were interpolated from the human IgG calibration curve on each plate, 
with a set of 40 repeated samples processed on each plate used to normalise assays run across 
different days. Values were then multiplied by the serum dilution score (i.e., 4000) for ease of 
data presentation. 
 Secretory IgA. Unstimulated passive drool saliva samples were obtained immediately 
prior to, and following, viewing the positive mood or neutral control video. Participants were 
asked to allow saliva to accumulate in their mouth for two minutes, passing saliva into 
polypropylene vials through a SalivaBio collection aid (Salimetrics/Stratech). All vials were 
weighed before and after saliva collection to determine salivary flow rate. Samples were 
stored at -20°C until analysis. Secretory IgA levels were determined using a commercial 
indirect ELISA kit, according to manufacturer instructions (see Salimetrics, 2017). Secretory 
IgA secretion rate (µg/min) was calculated by multiplying secretory IgA concentration from 
the assay by salivary flow rate, divided by the total collection time. 
 Statistical Analysis 
Statistical analyses were performed using IBM SPSS Statistics (version 25) and 
GraphPad Prism (version 7). The primary outcome was between group differences in state 
affect following the intervention or neutral control video. A priori sample size calculations 
indicated a sample of 102 participants would be needed to detect a medium-sized (d=0.5) 
between group effect in state affect scores in a one-tailed independent samples t-test with 
80% power. A recent meta-analysis we conducted of brief-mood enhancing interventions and 
immunity (Ayling et al., under review) suggested that successful brief (i.e., single session) 
interventions tend to have an average effect size on mood of around d=0.6, although there 
was significant heterogeneity. However, only one of the trials in that review included older 
adults and it is not yet established how large a mood effect would have to be to be ‘immune-
relevant’. Given this, we decided a priori that a medium sized effect on mood would be 
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comparable to other successful mood manipulations in younger cohorts and thus powered the 
trial accordingly. However, given our focus on between group differences we conducted a 
series of two-way analyses of variance comparing change in state affect scores across groups. 
Normality of distributions were assessed via the examination of histograms, with log2 or 
reciprocal transformations used to improve normality where possible if significant skew was 
evident. Paired sample t-tests, or non-parametric equivalents were used to explore within-
group effects. The potential influence of trait psychological characteristics on state affect 
responses was also explored. This involved a series of multiple regression analyses entering 
trait measures individually to predict post-intervention state affect scores controlling for pre-
intervention scores. Those trait measures that significantly predicted post-intervention state 
affect scores were entered simultaneously in a further model to test whether they were 
independent predictors.  
This trial was not a priori powered to detect significant between group differences in 
immunological outcomes but to determine if there was early evidence of an effect of the 
intervention on immunity and to explore the feasibility of a subsequent, appropriately 
powered trial. As such, results for immunological outcomes are primarily presented 
descriptively, with inferential tests conducted for the purpose of describing effect sizes. For 
secretory IgA outcomes we conducted a two-way analysis of variance comparing change 
from pre- to post-intervention between groups. For antigen specific IgG levels we conducted 
a series of one-way analyses of covariance comparing between group post-intervention IgG 
levels, in order to better control for pre-intervention differences. Given prior findings that 
trait psychological characteristics and health status can influence immunological responses to 
vaccination (Gross, Quinnan, Weksler, Setia, & Douglas, 1989; Marsland, Cohen, Rabin, & 
Manuck, 2006), we explored this across the entire cohort. To do this, a series of multiple 
regression analyses predicting post-intervention antigen-specific IgG were conducted 
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controlling for pre-intervention IgG levels and condition in step one, with trait psychological 
characteristics and health status entered individually in step two. Where multiple significant 
predictors were identified they were entered simultaneously in a further model to test whether 
they were independent predictors.  
As levels of missing outcome data were low (see supplementary appendix) and found 
to be missing completely at random (Little’s MCAR test: χ2(237) = 236.12, p = .504), we 
performed intention-to-treat analyses with listwise deletion for analyses where follow-up data 
were missing. We also performed per-protocol analyses excluding three participants (two 
from neutral control group, one from positive mood group) who did not complete study 
activities as intended (one was observed putting the tablet down and not watching the 
presented stimuli, one was observed watching another nearby participant’s tablet screen, and 
one was delayed in receiving their vaccine after completing tablet activities). Nearly all per-
protocol analyses did not result in any differing interpretations of the results presented below, 
thus only those which potentially impact on findings are presented here. 
Results 
Participant Recruitment & Randomisation 
Figure 1 shows the flow of participants through the study. Of the 1131 patients invited 
to participate, 106 (9.4%) consented. Of these 103 (97.2%) attended the appointment to 
receive their vaccination and were randomised to view the intervention or neutral control 
video. Retention throughout the study was high, with 102 (96.2%) participants attending 
follow-ups at four weeks post-vaccination, and 98 attending follow-ups at 16 weeks post-
vaccination (92.5%). Table 1 shows the baseline characteristics of participants in each group. 
Pre-intervention there were no significant differences between groups on any demographic, 
psychological, or immunological factors.  
Psychological Outcomes 
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State affect outcomes. We performed two-way mixed analyses of variance to compare the 
effects of the positive mood intervention and neutral control videos on state affect. Pre- and 
post-intervention scores on state affect measures can be seen in Table 2. Participants in the 
positive mood group had significantly greater improvements from pre- to post-intervention 
for slider valence [F(1,98) = 6.97, p = .010, partial η2 = .066, 90% CI (.009, .157)], and 
pictorial positive affect scores [F(1,96) = 8.83, p = .004, partial η2 = .084, 90% CI (.017, 
.181)] as indicated by significant time by group interactions. There were no statistically 
significant time by group interactions for slider-arousal [F(1,98) = 3.36, p = .070, partial η2 = 
.033, 90% CI (.000, .108)] or PANAS scores [positive affect: F(1,99) = 0.19, p = .668, partial 
η2 = .002 , 90% CI (.000, .039); negative affect: F(1,101) = 0.22, p = .642, partial η2 = .002, 
90% CI (.000, .040)].  
 Paired Wilcoxon signed rank tests examining state affect in the groups individually 
showed that following the intervention the positive mood group significantly increased in 
slider-valence (Z = -4.21, p < .001, r = .60), slider-arousal (Z = -2.92, p = .003, r = .42), and 
pictorial positive affect scores (Z = -3.70, p < .001, r = .53), significantly decreased in 
PANAS negative affect scores (Z = -3.95, p < .001, r = -.51), but had no statistically 
significant change in PANAS positive affect scores (Z = -1.66, p = .098, r = .23). In contrast, 
there were no significant changes in the neutral control group following viewing the video 
(Slider-Valence: Z = -.24, p = .810, r = .03; Slider-Arousal: Z = -.11, p = .912, r = -.02; 
pictorial positive affect scores: Z = -.13, p = .895 r = -.02; PANAS negative affect: Z = -1.93, 
p = .053, r = -.27; PANAS positive affect: Z = -.64, p = .524, r = .09). In per protocol 
analyses, the decrease in PANAS negative affect scores in the neutral control group became 
statistically significant (Z = -1.99, p = .046). 
Influence of trait psychological characteristics on state affect outcomes. Multiple 
regression analyses were conducted to examine the influence of trait psychological 
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characteristics on state affect responses. Within the positive mood group, higher slider-
valence and slider-arousal scores following the intervention (controlling for pre-intervention 
scores) were significantly predicted by lower trait negative affect (slider-valence: β = -.312, p 
= .003. Model: F(2, 44) = 40.37, p < .001, R2 = .631; slider-arousal: β = -.348, p = .003. 
Model: F(2, 44) = 43.68, p < .001, R2 = .665) and trait emotional reactivity (slider-valence: β 
= -.274, p = .008. Model: F(2, 43) = 34.12, p < .001, R2 = .613; slider-arousal: β = -.247, p = 
.027. Model: F(2, 43) = 34.14, p < .001, R2 = .614) in separate regression models. Entering 
trait negative affect and emotional reactivity into regression models simultaneously indicated 
neither were independent significant predictors above pre-intervention scores2. Higher 
pictorial positive affect scores following the intervention were significantly predicted by 
lower trait negative affect (β = -.438, p = .001. Model: F(2, 43) = 10.92, p < .001, R2 = .337) 
and higher trait optimism (β = .305, p = .033. Model: F(2, 44) = 5.70, p = .006, R2 = .206) 
when considered separately. However, when entered into the model simultaneously only trait 
negative affect was an independent significant predictor (β = -.407, p = .008. Model: F(3, 40) 
= 7.61, p < .001, R2 = .316). No trait psychological characteristics significantly predicted 
state PANAS outcomes in the positive mood intervention group following the intervention. In 
the neutral control group, higher slider-arousal scores following the intervention were 
predicted by greater trait positive affect (β = .362, p = .016. Model: F(2, 42) = 6.48, p = .004, 
R2 = .236) and higher PANAS negative affect scores following the intervention were 
predicted by lower trait positive affect scores (β = -.357, p = .035. Model: F(2, 42) = 4.22, p 
= .021, R2 = .17). 
Immunological Outcomes 
                                                 
2 In per protocol analysis, for slider-arousal scores only trait negative affect was an independent significant predictor above pre-intervention 
scores (β = -.27, p = .048. Model: F(3, 40) = 28.41, p < .001, R2 = .681) 
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Secretory IgA. Only 81 participants (37 neutral control group, 44 positive mood group) 
produced sufficient saliva for analysis at both pre- and post-intervention. Pre- and post-
intervention s-IgA levels can be seen in Table 2. We conducted two-way mixed analyses of 
variance, to compare the effects of the positive mood intervention and neutral control videos 
on s-IgA secretion rates. There was no significant time by group interaction in post-
intervention secretory IgA rates [F(1, 79) = .00, p = .996, partial η2 < .001 , 90% CI (.000, 
.000)]. There was however a significant main effect of time, such that secretory IgA 
increased over time across groups [F(1, 79) = 20.64, p < .001, partial η2 = .207 , 90% CI 
(.087, .327)]. Paired sample t-tests examining groups individually revealed secretory IgA 
rates significantly increased from pre-video to post-video samples in both positive mood 
intervention [t(43) = -3.36, p = .002, d = .51] and neutral control groups [t(36) = -3.08, p = 
.004, d = .51]. 
Influenza-specific IgG. As expected, IgG antibody levels for all strains significantly 
increased following vaccination [B/Brisbane: F(2, 192) = 27.78, p < .001, partial η2 = .22 , 
90% CI (.139, .300); B/Phucket: F(1.85, 177.65) = 41.82, p < .001, partial η2 = .30 , 90% CI 
(.209, .382); A/Hong-Kong: F(2, 192) = 16.71, p < .001, partial η2 = .15 , 90% CI (.074, 
.219); A/Michigan: F(1.74, 165.68) = 36.90, p < .001, partial η2 = .28 , 90% CI (.183, .361)]. 
Pairwise comparisons (Bonferroni-adjusted) revealed that for both B strains, IgG levels 
significantly increased from baseline to four weeks post-vaccination (B/Brisbane: Mdiff(log) = 
0.24, p < .001; B/Phucket: Mdiff(log)  = 0.48, p <.001) and from four to 16 weeks post-
vaccination (B/Brisbane: M diff(log) = 0.14, p = .016; B/Phucket: Mdiff(log) = 0.24, p = .014). For 
both A strains, IgG levels were significantly higher from baseline at both 4 and 16 weeks 
post-vaccination (A/Hong-Kong: four weeks - Mdiff(log) = 0.34, p < .001;  16 weeks - Mdiff(log) 
= 0.24, p < .001; A/Michigan: four weeks -  Mdiff(log) = 0.40, p <.001; 16 weeks - Mdiff(log) = 
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0.33, p < .001), but did not significantly differ between four and 16 weeks post-vaccination 
(A/Hong-Kong: Mdiff(log) = -0.10, p = .267; A/Michigan: Mdiff(log) = -0.08, p = .250). 
One way analyses of covariance showed that after adjusting for baseline antibody 
levels, mean post-vaccination antibody levels were not statistically significantly different 
between groups [A/Hong-Kong: four weeks - F(1, 99) = 0.61, p = .438, partial η2 = .006, 
90% CI (.000, .055);  16 weeks - F(1, 95) = 0.43, p = .516, partial η2 = .004 , 90% CI (.000, 
.051); A/Michigan: four weeks - F(1, 99) = 0.18, p = .671, partial η2 = .002 , 90% CI (.000, 
.038);  16 weeks - F(1, 94) < 0.01, p = .980, partial η2 < .001 , 90% CI (.000, .000); 
B/Brisbane: four weeks – F(1, 99) = 0.69, p = .409, partial η2 = .007 , 90% CI (.000, .057);  
16 weeks - F(1, 95) = 0.79, p = .377, partial η2 = .008 , 90% CI (.000, .062); B/Phuket: four 
weeks - F(1, 99) = 0.02, p = .892, partial η2 < .001 , 90% CI (.000, .008);  16 weeks - F(1, 
95) = 0.64, p = .426, partial η2 = .007, 90% CI (.000, .058)]  although point-estimates for all 
effect sizes were in the predicted direction, favouring the positive mood intervention over 
neutral control (see Figure 2). The only exception to this was in per protocol analyses, for 
A/Michigan IgG levels at 16 weeks post-vaccination. 
Influence of trait measures on IgG outcomes. To examine the role of trait 
psychological characteristics and health status on IgG responses to vaccination, irrespective 
of group assignment, a series of linear regression models were performed. These showed trait 
positive affect was a significant independent predictor above pre-intervention IgG levels and 
condition of B/Phuket IgG levels at 16 weeks post-vaccination [β = .172, p = .045. Model: 
F(3, 86) = 18.30, p < .001, R2 = .390, ΔR2 = .029, ΔF (1, 86) = 4.15, p = .045]. Trait negative 
affect significantly predicted the B/Phuket IgG levels at 4 weeks post-vaccination [β = .148, p 
= .037. Model: F(3, 87) = 39.00, p < .001, R2 = .559, ΔR2 = .022, ΔF(1, 87) = 4.48, p = .037]. 
Both trait positive affect and optimism were predictive of B/Brisbane IgG levels at 16 weeks 
post-vaccination [trait positive affect: β = .147, p = .033. Model: F(3, 86) = 44.71, p < .001, 
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R2 = .596, ΔR2 = .021, ΔF(1, 86) = 4.71, p = .033; trait optimism: β = .132, p = .049. Model: 
F(3, 87) = 47.51, p < .001, R2 = .621, ΔR2 = .017, ΔF(1, 87) = 3.99, p = .049] when 
considered individually, but when entered simultaneously neither were significant 
independent predictors. In per-protocol analyses, these trait predictors of B/Brisbane IgG at 
16 weeks post-vaccination were not statistically significant (trait positive affect: β = .133, p = 
.055. Model: F(3, 84) = 44.19, p < .001, R2 = .612, ΔR2 = .018, ΔF(1, 84) = 3.80, p = .055; 
trait optimism: β = .115, p = .089. Model: F(3, 85) = 46.95, p < .001, R2 = .624, ΔR2 = .013, 
ΔF(1, 85) = 2.95, p = .089). 
Feasibility Measures 
As shown in Figure 1, participant uptake was 9.4%. Other data on feasibility captured 
during the trial also suggested that most trial activities were well tolerated by participants. 
The only exception to this was the collection of saliva samples, which participants reported 
difficulties with and resulted in 21% of participants failing to produce samples. There were 
only three noted protocol violations and high levels of participant retention. Healthcare usage 
attributable to influenza-like symptoms during the six months were similar between groups 
(see supplementary appendix).   
Discussion 
The primary aim of this trial was to examine whether a brief intervention was able to 
enhance positive mood at the time of vaccination in a clinical context. Secondary aims 
included exploratory analyses of the effects of the intervention on non-specific and influenza-
specific immunity. Below, we discuss our findings in relation to each of these outcomes, as 
well as exploring the feasibility of a future larger trial. 
Intervention Effects on Mood 
With regard to mood outcomes, we observed that in a clinical setting the positive 
mood intervention resulted in positive affect improvements, compared with a neutral control 
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intervention. The increase in positive affect was seen across all our state affect measures 
apart from the PANAS, for which negative affect scores decreased in both groups (though not 
significantly in the neutral control arm) and positive affect scores showed no change in either 
group. The reasons for the divergent effects the PANAS positive affect subscale are unclear. 
One explanation for this may relate to the orthogonal nature of the PANAS dimensions, 
which were devised to be quasi-independent (Watson, 1988). As such, the positive affect 
subscale does not include many adjectives typically associated with positive mood (e.g., 
happy, cheerful), but which were perhaps better captured in the other state affect measures 
included in this trial. We further note that in a recent review we conducted of single session 
interventions and immunity (Ayling et al., under review), all interventions that showed 
significant improvements in PANAS subscales were considerably longer (≥1 hour) than the 
intervention examined here (e.g., Kiecolt-Glaser et al., 2008; Kreutz, Bongard, Rohrmann, 
Hodapp, & Grebe, 2004).  
That significant improvements in state affect were observed for the other measures is 
particularly noteworthy given that participants showed high mean levels of positive affect 
pre-intervention. This introduced the possibility of a ceiling effect (i.e., limiting the potential 
for large improvements in state affect). Indeed, it is worth noting that the largest 
improvements in state affect were observed in participants with higher levels of trait negative 
affect at baseline. These participants also scored lower on all pre-intervention state affect 
measures (all p’s <.05). Thus, the observed moderation may simply be due to the fact these 
individuals had greater scope for their scores to increase following the intervention.  
Intervention Effects on Non-specific Immunity  
To explore whether the positive mood intervention resulted in any rapid changes to a 
non-specific aspect of immunity, we measured secretory IgA levels pre- and post-
intervention. We observed significant increases in secretory IgA secretion among participants 
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viewing the positive mood intervention. However, we saw a similar secretory IgA increase in 
the neutral control group indicating, in this case, that any secretory IgA changes cannot be 
attributable to a positive mood increase, and is likely best explained as an artefact of the 
research process common to both groups. Given that PANAS negative affect scores 
decreased from before to after the intervention in both groups (though this did not reach 
statistical significance in the control group [Z = -1.93, p = .053, r = -.27]) we speculate that 
the observed increase in secretory IgA levels across groups could reflect some form of 
relaxation effect. Rest alone has previously been shown to result in increases in secretory IgA 
levels (Donoyama & Shibasaki, 2010) therefore it may be that just the act of sitting quietly 
and viewing a 15 minute video was sufficient to result in these changes. Notably, many prior 
studies reporting an increase in secretory IgA concentration following positive mood 
induction have adopted cohort or crossover designs without a neutral control group (e.g., 
Burns, Harbuz, Hucklebridge, & Bunt, 2001; Lefcourt, Davidson-Katz, & Kueneman, 1990). 
In contrast, studies with control groups similar to ours typically show a similar pattern of 
findings (e.g., Donoyama, Munakata, & Shibasaki, 2010; Donoyama & Shibasaki, 2010).  
Collectively, these findings highlight the importance of future studies of secretory IgA and 
mood including neutral control conditions, to avoid the potentially erroneous attribution of 
secretory IgA changes to increases in positive mood. 
Intervention Effects on Vaccine-specific Immunity  
In examining the intervention effects on antibody responses to a quadrivalent 
influenza vaccination, we observed no statistically significant differences between 
participants who viewed the positive affect intervention to the neutral control group. This is 
not surprising given that the trial was not powered for this outcome. Instead our aim was 
exploratory, in that we sought to determine if there was early evidence of an effect of the 
intervention on immunity and to explore the feasibility of a subsequent, appropriately 
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powered trial. In that regard, we observed that for most strains at both 4 and 16 weeks post-
vaccination, the point-estimates of effect favoured the positive affect intervention and were 
small. One interpretation of these findings is that they suggest that the intervention, whilst 
demonstrating an effect on positive mood, is unlikely to result in an effect on antibody 
responses of sufficient magnitude to be clinically relevant. But such a conclusion should be 
interpreted in the context of two further issues. First, it could be argued that any effect in 
clinical practice could potentially be larger than reported here. Our design included an active 
neutral control as the comparison arm, rather than usual care (which would have been no 
stimuli). This may have served to attenuate any observed between group differences on mood 
and, in turn, on immune outcomes. Second, while we note due caution is warranted in over-
extrapolating effect size estimations from pilot trials (Bell & Julious, 2018; Kraemer, Mintz, 
Noda, Tinklenberg, & Yesavage, 2015; Leon, Davis, & Kraemer, 2011), effect sizes of the 
magnitude observed here are not necessarily trivial when the intervention is produced at low 
cost and could be implemented at high volume. Even modest improvements to vaccine-
related clinical outcomes could be of substantial benefit to patients and the health service, 
given the large number of vaccine recipients annually. Indeed, other low-cost high-volume 
interventions have been widely adopted in clinical practice for the purpose of preventing 
disease, even where effect sizes are relatively small (e.g., statins for the prevention of major 
cardiovascular events: d = 0.15; Leucht, Helfer, Gartlehner, & Davis, 2015). We propose, 
therefore, that further research is warranted involving trials in which changes in antibody 
levels are the primary outcome and the comparator arm is usual care. Only then will we be 
able to determine definitively if interventions that enhance positive mood are able to enhance 
vaccine effectiveness and reduce the burden of disease. 
In terms of the relationship between positive affect and antibody responses to 
vaccination more broadly, we found across the entire sample, that higher levels of trait 
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positive affect were also associated with significantly larger antibody responses to the 
influenza vaccination (at least for the B strains of the vaccine). This replicates prior findings 
demonstrating associations between trait, or long-term, positive affect and antibody responses 
to vaccination (Ayling et al., 2018; Marsland et al., 2006). Mechanisms underpinning this 
association continue to be elucidated and likely include both direct effects of the central 
nervous system on immune function (Marques-Deak et al., 2005; Pressman & Cohen, 2005) 
and indirect pathways. Whether these pathways can be leveraged to improve vaccine-related 
outcomes in older adults remains a further avenue for researchers to explore. 
Feasibility of a Larger Trial 
This study supports the feasibility of conducting a future larger trial of the 
intervention, potentially including an examination of effects on non-surrogate clinical 
endpoints. The vast majority of participants receiving their allocated intervention as intended, 
and high retention rates were observed across all follow-ups. While the uptake rate (9.4%) in 
this trial was consistent with our prior studies in this area (Ayling et al., 2018) that have also 
relied on a low-intensity recruitment approach (i.e., single invitation letter), there remains the 
potential to improve these uptake rates with a more intensive approach. Evidence based 
strategies for boosting recruitment rates which could be considered include telephone 
reminders to non-responders and in-person patient screening and recruitment approaches 
(Ngune, Moyez, Dadich, Lotriet, & Sriram, 2012; Treweek et al., 2018). Implementing such 
strategies would likely be beneficial in increasing uptake rates in a future larger trial.  
Limitations and Strengths 
It is important to acknowledge that our results here relate to a quadrivalent egg-
derived influenza vaccine, and we do not know whether these findings will generalise to 
future vaccines in an evolving landscape of approved influenza vaccines for use in older 
adults. For example, the 2018/19 influenza vaccination season saw the introduction of  an 
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adjuvanted trivalent vaccine in the NHS (Wise, 2018), and the European Medicine Agency 
(2018) recently approved cell-based quadrivalent and high-dose egg-derived trivalent 
vaccines for use in 2019/20. Further research is needed to establish whether any benefits of a 
brief positive mood intervention prior to vaccination are evident with different vaccine 
formulations.  
We also note that our sample were self-selecting, and therefore may not be entirely 
representative of the older adult population. For the majority of demographic variables 
assessed, we were successful in recruiting across a broad spectrum of older adults. However, 
one concern is the lack of ethnic diversity of the recruited sample, which was almost 
exclusively made up of those who identified as White-British. Moving towards a larger trial, 
the adoption of recommendations for increasing ethnic minority adults into clinical research 
(e.g., Areán, Alvidrez, Nery, Estes, & Linkins, 2003; Areán & Gallagher-Thompson, 1996) 
will need to be considered. 
This is the first trial to examine the effects of a brief positive mood intervention 
administered prior to a quadrivalent influenza vaccine in primary care. We adopted a 
controlled, single-blinded study design and made attempts to minimise the effects of demand 
characteristics, by concealing aspects of the research from participants, namely by not 
highlighting there were two groups, one of which was a neutral control. However, 
participants were aware the study was examining the relationship between mood and 
influenza vaccination responses. As such, we cannot rule out the possibility that the observed 
effects on self-reported mood outcomes are influenced by this knowledge. Relatedly, while 
steps were taken to keep researchers blind to participant allocation, due to common reactions 
of participants to the positive mood intervention (e.g., laughter) it is possible that researchers 
could have inferred group assignment for some participants. As the main outcome measures 
were either participant reported immediately post-intervention (state affect), or machine-read 
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optical absorbance values (immune), any lack of researcher blinding is unlikely to have 
influenced the study findings.  
Concluding Remarks 
A brief 15-minute intervention resulted in significant improvements in positive mood 
in older adults prior to receiving their annual influenza vaccination. Point-estimates of effects 
on antibody responses indicated that effects on antibody were in the predicted direction. 
Further research is now needed to establish whether a brief intervention could act as a low-
cost, high volume method for enhancing the effectiveness of influenza vaccination in older 
people.    
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Figure 1: Flow Diagram of Participants 
 
 
 
Figure 2: Antigen specific IgG responses to vaccination by group. Bars are antilog 
transformed pre-vaccination IgG adjusted-means. Error bars are 95% confidence intervals. 
 
MOOD AND INFLUENZA VACCINATION IN OLDER ADULTS   35 
 
 
 
 
 
 
MOOD AND INFLUENZA VACCINATION IN OLDER ADULTS   36 
 
 
 
Table 1: Participant demographics by study arm+ 
Variable Positive 
Mood 
Intervention 
Neutral 
Control 
 
Test for Between-Condition 
Differences 
Age - yr 72.6 (4.6) 73.3 (5.1) t(100) = 0.71, p = .480 
Female sex – n (%) 22 (42.3) 30 (58.8) χ2(1) = 3.19, p = .074 
White Ethnicity – n (%) 51 (98.1) 48 (94.1) χ2(2) = 1.05, p = .591 
Marital Status – n (%) χ2(4) = 6.57, p = .161 
Married 34 (65.4) 29 (56.9)  
Single, never married 0 (0) 3 (5.9)  
Separated/divorced 9 (17.3) 4 (7.8)  
Widowed 4 (7.7) 8 (15.7)  
Cohabiting 3 (5.8) 3 (5.9)  
Did not respond 2 (3.8) 4 (7.8)  
Highest Level of Education – n (%)  χ2(3) = 3.08, p = .380 
School 37 (71.2) 40 (78.4)  
Undergraduate 2 (3.8) 0 (0)  
Postgraduate 0 (0) 1 (2.0)  
Other 8 (15.4) 8 (15.7)  
Did not respond 5 (9.6) 2 (3.9)  
Living Independently – n (%) 47 (90.4) 49 (98.0) χ2(1) = 2.67, p = .102 
Highest Ever Total Household Income – n (%) χ2(4) = 1.80, p = .773 
≤ £14,999 17 (32.7) 16 (31.4)  
£15,000–£24,999  16 (30.8) 17 (33.3)  
£25,000–£34,999 8 (15.4) 4 (7.8)  
£35,000–£49,000 7 (13.5) 5 (0.8)  
£50,000–£74,999 1 (1.9) 2 (3.9)  
£75,000–£99,000 0 (0) 0 (0)  
≥ £100,000 0 (0) 0 (0)  
Did Not Respond 3 (5.8) 7 (13.7)  
Current Smoker – n (%) 4 (7.7) 4 (7.8) χ2(1) = 0.003, p = .954 
Total Health Status  555.7 
(175.1)1 
555.1 (169.9) t(95) = -0.02, p = .988 
Trait Positive Affect (PANAS) 33.5 (8.6) 33.8 (8.1) U = 1104.5, Z = -.15, p =.878 
Trait Negative Affect (PANAS) 15.2 (6.7) 15.5 (6.4) U = 1013.5, Z = -.32, p =.753 
Trait Optimism  16.0 (4.8) 15.3 (4.5) t(94) = -.80, p = .424 
Trait Emotional Reactivity 39.9 (17.2) 41.3 (16.0) t(93) = .71, p = .481 
Pre-Vaccination IgG    
A/Michigan 187.2 (112.4) 156.6 (103.1) t(101) = -1.84, p = .069‡ 
A/Hong Kong 238.0 (119.9) 241.0 (158.1) t(101) = -0.46, p = .646‡ 
B/Brisbane 107.0 (54.1) 118.9 (78.7) t(92.32) = 0.19, p = .850‡ 
B/Phuket 144.4 (85.1) 183.2 (146.2) t(101) = 1.01, p = .313‡ 
+Mean (standard deviation) unless otherwise specified 
‡ Based on log-transformed values 
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Table 2: Pre- and Post-Intervention Momentary Affect and S-IgA scores by group [Mean (SD)] 
Variable 
Positive Mood Condition(n=52) Neutral Control Condition 
(n=51) 
Pre-Intervention Post-Intervention Pre-
Intervention 
Post-
Intervention 
Slider-valence 79.5 (19.2) 87.4 (15.7) 80.5 (18.1) 79.8 (20.8) 
Slider-arousal 79.9 (19.0) 83.7 (16.8) 80.9 (20.1) 79.8 (20.3) 
Pictorial 3.7 (1.5) 4.7 (1.1) 4.0 (1.5) 4.0 (1.5) 
Positive Affect 
(PANAS) 
34.3 (7.3) 35.0 (8.4) 34.6 (7.2) 35.0 (7.6) 
Negative Affect 
(PANAS) 
12.3 (4.0) 11.1 (3.0) 12.3 (4.0) 11.4 (2.3) 
Salivary IgA (g/min) 
+ 
81.0 (76.4) 116.7 (107.5) 94.1 (94.2)  144.7 (142.5) 
+Based on positive mood condition: n=46; neutral control condition: pre-intervention n=42, post 
intervention n=41  
 
 
